Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.55 USD | +0.71% | +4.10% | +28.64% |
04-09 | Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating | MT |
04-08 | Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint | MT |
Business Summary
Number of employees: 10,000
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Women's Health - Nexplanon/Implanon NXT
13.3
%
| 834 | 13.5 % | 830 | 13.3 % | -0.48% |
Cardiovascular - Atozet
8.3
%
| 457 | 7.4 % | 519 | 8.3 % | +13.57% |
Respiratory - Singulair
6.5
%
| 411 | 6.7 % | 404 | 6.5 % | -1.70% |
Other - Other
5.1
%
| 326 | 5.3 % | 319 | 5.1 % | -2.15% |
Cardiovascular - Zetia
4.9
%
| 357 | 5.8 % | 306 | 4.9 % | -14.29% |
Cardiovascular - Cozaar/Hyzaar
4.5
%
| 323 | 5.2 % | 281 | 4.5 % | -13.00% |
Biosimilars - Renflexis
4.4
%
| 226 | 3.7 % | 278 | 4.4 % | +23.01% |
Other Non-opioid Pain, Bone and Dermatology
4.4
%
| 273 | 4.4 % | 275 | 4.4 % | +0.73% |
Women's Health - Follistim AQ
4.2
%
| 229 | 3.7 % | 262 | 4.2 % | +14.41% |
Non-opioid Pain, Bone and Dermatology - Arcoxia
4.1
%
| 241 | 3.9 % | 257 | 4.1 % | +6.64% |
Respiratory - Nasonex
4.0
%
| 238 | 3.9 % | 253 | 4.0 % | +6.30% |
Respiratory - Dulera
3.1
%
| 180 | 2.9 % | 194 | 3.1 % | +7.78% |
Other Women's Health
2.7
%
| 204 | 3.3 % | 171 | 2.7 % | -16.18% |
Non-opioid Pain, Bone and Dermatology - Fosamax
2.5
%
| 152 | 2.5 % | 159 | 2.5 % | +4.61% |
Biosimilars - Ontruzant
2.5
%
| 122 | 2.0 % | 155 | 2.5 % | +27.05% |
Other Cardiovascular
2.5
%
| 159 | 2.6 % | 155 | 2.5 % | -2.52% |
Women's Health - NuvaRing
2.4
%
| 173 | 2.8 % | 152 | 2.4 % | -12.14% |
Respiratory - Clarinex
2.2
%
| 125 | 2.0 % | 136 | 2.2 % | +8.80% |
Women's Health - Marvelon/Mercilon
2.1
%
| 110 | 1.8 % | 134 | 2.1 % | +21.82% |
Cardiovascular - Vytorin
2.1
%
| 130 | 2.1 % | 129 | 2.1 % | -0.77% |
Other - Propecia
2.0
%
| 125 | 2.0 % | 125 | 2.0 % | 0.00% |
Other
1.9
%
| 146 | 2.4 % | 121 | 1.9 % | -17.12% |
Women's Health - Ganirelix Acetate Injection
1.8
%
| 123 | 2.0 % | 110 | 1.8 % | -10.57% |
Other - Proscar
1.5
%
| 101 | 1.6 % | 97 | 1.5 % | -3.96% |
Non-opioid Pain, Bone and Dermatology - Diprospan
1.5
%
| 122 | 2.0 % | 91 | 1.5 % | -25.41% |
Other Respiratory
1.2
%
| 83 | 1.3 % | 77 | 1.2 % | -7.23% |
Biosimilars - Brenzys
1.2
%
| 75 | 1.2 % | 73 | 1.2 % | -2.67% |
Cardiovascular - Rosuzet
1.1
%
| 71 | 1.1 % | 70 | 1.1 % | -1.41% |
Biosimilars - Hadlima
0.7
%
| 19 | 0.3 % | 44 | 0.7 % | +131.58% |
Women's Health - Jada
0.7
%
| - | - | 43 | 0.7 % | - |
Biosimilars - Aybintio
0.7
%
| 39 | 0.6 % | 43 | 0.7 % | +10.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe and Canada
26.7
%
| 1,631 | 26.4 % | 1,673 | 26.7 % | +2.58% |
United States
23.6
%
| 1,437 | 23.3 % | 1,478 | 23.6 % | +2.85% |
Asia Pacific and Japan
18.0
%
| 1,143 | 18.5 % | 1,129 | 18.0 % | -1.22% |
Latin America, Middle East, Russia and Africa
15.4
%
| 895 | 14.5 % | 965 | 15.4 % | +7.82% |
China
13.8
%
| 917 | 14.9 % | 864 | 13.8 % | -5.78% |
Global
2.5
%
| 151 | 2.4 % | 154 | 2.5 % | +1.99% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kevin Ali
CEO | Chief Executive Officer | 63 | 21-06-01 |
Matthew Walsh
DFI | Director of Finance/CFO | 57 | 21-06-01 |
Chief Tech/Sci/R&D Officer | 54 | 23-09-04 | |
Rachel Stahler
CTO | Chief Tech/Sci/R&D Officer | 48 | 20-12-31 |
Marcel van Duin
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
Jennifer Halchak
IRC | Investor Relations Contact | - | - |
Charlotte Owens
PRN | Corporate Officer/Principal | - | 23-09-04 |
Kirke Weaver
LAW | General Counsel | - | 22-06-30 |
Vittorio Nisita
PRN | Corporate Officer/Principal | 56 | 21-06-01 |
Joseph Morrissey
PRN | Corporate Officer/Principal | 59 | 21-06-01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Rochelle Lazarus
BRD | Director/Board Member | 76 | 21-06-01 |
Carrie Cox
CHM | Chairman | 66 | 21-06-01 |
Robert Essner
BRD | Director/Board Member | 76 | 21-06-01 |
Helene Gayle
BRD | Director/Board Member | 69 | 21-06-01 |
Shalini Sharp
BRD | Director/Board Member | 49 | 21-06-01 |
Director/Board Member | 70 | 21-06-01 | |
Philip Ozuah
BRD | Director/Board Member | 61 | 21-06-01 |
Grace Whiteford
BRD | Director/Board Member | 61 | 21-06-01 |
Director/Board Member | 55 | 21-06-01 | |
Kevin Ali
CEO | Chief Executive Officer | 63 | 21-06-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 255,638,256 | 255,270,098 ( 99.86 %) | 0 | 99.86 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmaceuticals: Major
| |
Organon (India) Pvt Ltd.
Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Dashtag
Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK. |
Financial Conglomerates
|
GTS FI BV
GTS FI BV Financial ConglomeratesFinance Part of Organon & Co., GTS FI BV is an investment holding Dutch company that provides financing services. The private company is located in Netherlands. |
Financial Conglomerates
|
Organon Finance 1 LLC
|
Finance/Rental/Leasing
|
Organon LLC
| |
Organon Foreign Debt Co-Issuer BV
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.64% | 4.77B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- OGN Stock
- Company Organon & Co.